BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody
Articolo
Data di Pubblicazione:
2018
Abstract:
BRAF and MEK inhibitors (BRAF/MEKi) favor melanoma-infiltrating lymphocytes, providing the rationale for current combinatorial trials with anti-PD1 antibody. A portion of melanoma cells may express PD1, and anti-PD1 antibody could have a direct anti-tumor effect. Here, we explore if BRAF/MEKi modulate rates of PD1+ melanoma cells, supporting an additional - lymphocyte-independent - basis for their therapeutic combination with anti-PD1 antibody.
Tipologia CRIS:
03A-Articolo su Rivista
Keywords:
BRAF, MEK inhibitors, PD1-positive, melanoma,lymphocyte-independent, synergism,anti-PD1, antibody
Elenco autori:
Sanlorenzo, Martina; Vujic, Igor; Floris, Arianna; Novelli, Mauro; Gammaitoni, Loretta; Giraudo, Lidia; Macagno, Marco; Leuci, Valeria; Rotolo, Ramona; Donini, Chiara; Basiricò, Marco; Quaglino, Pietro; Fierro, Maria Teresa; Giordano, Silvia; Sibilia, Maria; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario
Link alla scheda completa:
Link al Full Text:
Pubblicato in: